Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 229

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers are Not Associated with Severe COVID-19 Infection in a Multi-Site UK Acute Hospital Trust

Open access
Bean, Daniel M., Kraljevic, Zeljko, Searle, Thomas, Bendayan, Rebecca, Kevin, O’Gallagher, Pickles, Andrew, Folarin, Amos, Roguski, Lukasz, Noor, Kawsar, Shek, Anthony, Zakeri, Rosita, Shah, Ajay M., Teo, James T.H., Dobson, Richard J.B. · 2020 · European Journal of Heart Failure

Published version of a preprint

Abstract

Aims: The SARS-CoV-2 virus binds to the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. It has been suggested that angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB), which are commonly used in patients with hypertension or diabetes and may raise tissue ACE2 levels, could increase the risk of severe COVID-19 infection. Methods and results: We evaluated this hypothesis in a consecutive cohort of 1200 acute inpatients with COVID-19 at two hospitals with a multi-ethnic catchment population in London (UK). The mean age was 68 ± 17 years (57% male) and 74% of patients had at least one comorbidity. Overall, 415 patients (34.6%) reached the primary endpoint of death or transfer to a critical care unit for organ support within 21 days of symptom onset. A total of 399 patients (33.3%) were taking ACEi or ARB. Patients on ACEi/ARB were significantly older and had more comorbidities. The odds ratio for the primary endpoint in patients on ACEi and ARB, after adjustment for age, sex and co-morbidities, was 0.63 (95% confidence interval 0.47–0.84, P < 0.01). Conclusions: There was no evidence for increased severity of COVID-19 in hospitalised patients on chronic treatment with ACEi or ARB. A trend towards a beneficial effect of ACEi/ARB requires further evaluation in larger meta-analyses and randomised clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1924

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 16

  1. Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 · DOI · Paper page
  2. Vuille-dit-Bille, 2015, Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors, Amino Acids, 47, 693, 10.1007/s00726-014-1889-6 · DOI · Paper page
  3. Kuster, 2020, SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?, Eur Heart J, 41, 1801, 10.1093/eurheartj/ehaa235 · DOI · Paper page
  4. Tomasoni, 2020, COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease, Eur J Heart Fail, 22, 957, 10.1002/ejhf.1871 · DOI · Paper page
  5. Danser, 2020, Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers, Hypertension, 75, 1382, 10.1161/HYPERTENSIONAHA.120.15082 · DOI · Paper page
  6. Bean, 2019, Semantic computational analysis of anticoagulation use in atrial fibrillation from real world data, PLoS One, 14, 10.1371/journal.pone.0225625 · DOI
  7. Kraljevic, 2019, MedCAT – medical concept annotation tool, arXiv
  8. Johnson, 2016, MIMIC-III, a freely accessible critical care database, Sci Data, 3, 10.1038/sdata.2016.35 · DOI · Paper page
  9. Linden, 2020, Conducting sensitivity analysis for unmeasured confounding in observational studies using E-values: the evalue package, Stata J, 20, 162, 10.1177/1536867X20909696 · DOI
  10. Li, 2020, Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China, JAMA Cardiol, 10.1001/jamacardio.2020.1624 · DOI · Paper page
  11. Mancia, 2020, Renin-angiotensin-aldosterone system blockers and the risk of Covid-19, N Engl J Med, 382, 2431, 10.1056/NEJMoa2006923 · DOI · Paper page
  12. Julius, 2004, Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study, J Am Coll Cardiol, 43, 1047, 10.1016/j.jacc.2003.11.029 · DOI
  13. Taylor, 2005, Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Circulation, 112, 3654, 10.1161/CIRCULATIONAHA.105.540443 · DOI
  14. Reynolds, 2020, Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19, N Engl J Med, 382, 2441, 10.1056/NEJMoa2008975 · DOI · Paper page
  15. Sama, 2020, Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors, Eur Heart J, 41, 1810, 10.1093/eurheartj/ehaa373 · DOI · Paper page
  16. de Simone, 2020, Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers

Cited by

See all 229

Metadata

Authors
Bean, D. M., Kraljevic, Z., Searle, T., Bendayan, R., Kevin, O., Pickles, A., Folarin, A., Roguski, L., Noor, K., Shek, A., Zakeri, R., Shah, A. M., Teo, J. T. H., & Dobson, R. J. B.
Venue
European Journal of Heart Failure
Published
2020-06-01
Volume
22
Issue
6
Pages
967-974
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W3030177929
Cited by
229
References
11
FWCI
6.61
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers are Not Associated with Severe COVID-19 Infection in a Multi-Site UK Acute Hospital Trust. https://app.cochat.ai/papers/10.1002/ejhf.1924
The paper
Bean, D. M., Kraljevic, Z., Searle, T., Bendayan, R., Kevin, O., Pickles, A., Folarin, A., Roguski, L., Noor, K., Shek, A., Zakeri, R., Shah, A. M., Teo, J. T. H., & Dobson, R. J. B. (2020). Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers are Not Associated with Severe COVID-19 Infection in a Multi-Site UK Acute Hospital Trust. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1924

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.